DK1313485T3 - Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion - Google Patents
Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktionInfo
- Publication number
- DK1313485T3 DK1313485T3 DK01964471T DK01964471T DK1313485T3 DK 1313485 T3 DK1313485 T3 DK 1313485T3 DK 01964471 T DK01964471 T DK 01964471T DK 01964471 T DK01964471 T DK 01964471T DK 1313485 T3 DK1313485 T3 DK 1313485T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor antagonist
- aldosterone receptor
- cognitive function
- improve cognitive
- aldosterone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22873800P | 2000-08-28 | 2000-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1313485T3 true DK1313485T3 (da) | 2005-12-27 |
Family
ID=22858397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01964471T DK1313485T3 (da) | 2000-08-28 | 2001-08-28 | Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion |
Country Status (10)
Country | Link |
---|---|
US (2) | US20020111337A1 (da) |
EP (1) | EP1313485B1 (da) |
JP (1) | JP2004507495A (da) |
AT (1) | ATE306272T1 (da) |
AU (1) | AU2001285318A1 (da) |
CA (1) | CA2419256A1 (da) |
DE (1) | DE60114027T2 (da) |
DK (1) | DK1313485T3 (da) |
ES (1) | ES2251505T3 (da) |
WO (1) | WO2002017895A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1453495A2 (en) | 2001-11-23 | 2004-09-08 | Akzo Nobel N.V. | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists |
NZ548754A (en) * | 2002-04-26 | 2008-06-30 | Schering Aktiengellschaft | Treatment of hypertension in women receiving hormone replacement therapy |
TW200400816A (en) | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
US7786101B2 (en) | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
AU2002368326A1 (en) * | 2002-11-05 | 2004-06-07 | Schering Aktiengesellschaft | Hormone replacement therapy with drospirenone |
ATE454155T1 (de) * | 2002-11-05 | 2010-01-15 | Bayer Schering Pharma Ag | Verwendung von drospirenon zur behandlung von hypertension |
WO2004060400A1 (ja) * | 2003-01-06 | 2004-07-22 | Mitsubishi Pharma Corp | 上皮成長因子受容体を分子標的とする抗精神病薬 |
US7485094B2 (en) * | 2003-09-30 | 2009-02-03 | Smithmarks, Inc. | Methods of diagnosis using pulse volume measurement |
EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
US20090265215A1 (en) * | 2008-04-22 | 2009-10-22 | Paul Bernhard Lindstrom | Methods and apparatus to monitor audience exposure to media using duration-based data |
WO2012059594A1 (en) * | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
US8933113B2 (en) | 2011-01-20 | 2015-01-13 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
EP2697203B1 (en) | 2011-04-13 | 2017-05-24 | Merck Sharp & Dohme Corporation | Mineralocorticoid receptor antagonists |
WO2013055606A1 (en) | 2011-10-13 | 2013-04-18 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
US9085568B2 (en) | 2011-10-13 | 2015-07-21 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
EP2765860B1 (en) | 2011-10-13 | 2016-08-17 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor antagonists |
AR091731A1 (es) | 2012-07-19 | 2015-02-25 | Merck Sharp & Dohme | Antagonistas del receptor de mineralocorticoides |
EP3373920A4 (en) * | 2015-11-13 | 2019-07-17 | Pietro Paolo Sanna | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO ALCOHOL CONSUMPTION |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133012A (en) * | 1961-06-28 | 1964-05-12 | Universal Oil Prod Co | Combination catalytic reforming process |
US3257390A (en) * | 1963-06-12 | 1966-06-21 | Merck & Co Inc | Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents |
AU538186B2 (en) * | 1980-03-07 | 1984-08-02 | Scotia Holdings Plc | Prostaglandin precursors |
FI77669C (fi) * | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
DE3506100A1 (de) * | 1985-02-18 | 1986-08-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
DE69716116T2 (de) * | 1996-12-11 | 2003-09-04 | Searle & Co | VERFAHREN ZUR HERSTELLUNG VON 3-KETO-7alpha-ALKOXYCARBONYL- delta4,5-STEROIDEN SOWIE ZWISCHENPRODUKTE |
DE19654609A1 (de) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
CZ20011590A3 (cs) * | 1998-11-06 | 2003-01-15 | G. D. Searle & Co. | Léčivo pro léčení kardiovaskulárních poruch a kompozice s obsahem inhibitoru enzymu konvertujícího angiotensin, antagonisty aldosteronu, kličkového diuretika a digoxinu |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
NZ514205A (en) * | 1999-03-05 | 2004-07-30 | G | Combination therapy of angiotensin converting enzyme inhibitor and the epoxy-steroidal aldosterone antagonist eplerenone for treatment of cardiovascular disease |
-
2001
- 2001-08-28 AU AU2001285318A patent/AU2001285318A1/en not_active Abandoned
- 2001-08-28 DK DK01964471T patent/DK1313485T3/da active
- 2001-08-28 DE DE60114027T patent/DE60114027T2/de not_active Expired - Fee Related
- 2001-08-28 AT AT01964471T patent/ATE306272T1/de not_active IP Right Cessation
- 2001-08-28 CA CA002419256A patent/CA2419256A1/en not_active Abandoned
- 2001-08-28 EP EP01964471A patent/EP1313485B1/en not_active Expired - Lifetime
- 2001-08-28 JP JP2002522869A patent/JP2004507495A/ja not_active Withdrawn
- 2001-08-28 WO PCT/US2001/026760 patent/WO2002017895A2/en active IP Right Grant
- 2001-08-28 US US09/941,206 patent/US20020111337A1/en not_active Abandoned
- 2001-08-28 ES ES01964471T patent/ES2251505T3/es not_active Expired - Lifetime
-
2005
- 2005-02-25 US US11/067,426 patent/US20060058274A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE306272T1 (de) | 2005-10-15 |
US20060058274A1 (en) | 2006-03-16 |
WO2002017895A3 (en) | 2003-02-06 |
DE60114027D1 (de) | 2006-02-23 |
US20020111337A1 (en) | 2002-08-15 |
EP1313485A2 (en) | 2003-05-28 |
ES2251505T3 (es) | 2006-05-01 |
JP2004507495A (ja) | 2004-03-11 |
WO2002017895A2 (en) | 2002-03-07 |
EP1313485B1 (en) | 2005-10-12 |
AU2001285318A1 (en) | 2002-03-13 |
CA2419256A1 (en) | 2002-03-07 |
DE60114027T2 (de) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1313485T3 (da) | Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion | |
PT1349839E (pt) | Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato | |
MY143366A (en) | Muscarinic acetylcholine receptor antagonists | |
AU3652102A (en) | Compounds and their uses | |
DK1339678T3 (da) | Selektive agonister til EP4-receptor til behandling af osteoporose | |
DE69929235D1 (de) | Spiro-indole als y5-rezeptor antagonisten | |
SG163564A1 (en) | Kinin antagonists for treating bladder dysfunction | |
HN2003000285A (es) | Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
ATE311200T1 (de) | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten | |
MA27901A1 (fr) | Antagonistes du recepteur de l'acetylcholine muscarinique | |
DK1117403T3 (da) | MGLUR5-antagonister til behandling af smerte og angst | |
NO20034311D0 (no) | CCR5-antagonister for behandling av AIDS | |
UY28646A1 (es) | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina | |
UY28645A1 (es) | Nuevos antagonistas del receptor muscarinico m3 de acetilcolina | |
NO20016246L (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
UY28417A1 (es) | Antagonistas de los receptores muscarinicos de la acetilcolina | |
BRPI0415281A (pt) | antagonistas de receptor de acetilcolina muscarìnico | |
MXPA05007605A (es) | Antagonista del receptor de androgenos. | |
AU1604001A (en) | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects | |
DE60126134D1 (de) | Crf-rezeptorantagonisten und diese betreffende verfahren | |
DK1146872T3 (da) | Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt | |
DE60015187D1 (de) | Urotensin-ii rezeptorantagonisten | |
EA200601592A1 (ru) | Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора | |
NO20031745L (no) | Inhibisjon av vekstfaktoravhengigheten til tumorceller | |
SE0001373D0 (sv) | NPY Y1 receptor agonists and antagonists |